Hangzhou Biotest Biotech Co.,Ltd.
Shanghai Stock ExchangeTotal Valuation
Hangzhou Biotest Biotech Co.,Ltd. carries a market capitalization of 5.32B, placing it among publicly traded companies globally. Its enterprise value stands at 3.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.32B |
| Enterprise Value | 3.66B |
Share Statistics
Hangzhou Biotest Biotech Co.,Ltd. currently has 149.33M shares outstanding.
| Shares Outstanding | 149.33M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Hangzhou Biotest Biotech Co.,Ltd. trades at a trailing price-to-earnings ratio of 47.48. The price-to-sales ratio is 10.51, and the price-to-book ratio stands at 3.37.
| PE Ratio | 47.48 |
| PS Ratio | 10.51 |
| PB Ratio | 3.37 |
| P/TBV Ratio | 2.54 |
| P/FCF Ratio | 62.62 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Hangzhou Biotest Biotech Co.,Ltd. trades at an EV/EBITDA multiple of 37.94 and an EV/FCF ratio of 44.01. The EV/Sales ratio of 7.39 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 37.94 provides insight into valuation relative to core operating earnings.
| EV / Sales | 7.39 |
| EV / EBITDA | 37.94 |
| EV / EBIT | 37.94 |
| EV / FCF | 44.01 |
Financial Position
Hangzhou Biotest Biotech Co.,Ltd. maintains a current ratio of 14.75, meaning it holds 14.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.01, indicating conservative leverage, while an interest coverage ratio of 18,408.82 demonstrates strong ability to service its debt obligations.
| Current Ratio | 14.75 |
| Quick Ratio | 13.31 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | 18,408.82 |
Financial Efficiency
Hangzhou Biotest Biotech Co.,Ltd. posts a return on equity of 7.09 and a return on invested capital of 3.49.
| Return on Equity (ROE) | 7.09 |
| Return on Assets (ROA) | 4.42 |
| Return on Invested Capital (ROIC) | 3.49 |
| Return on Capital Employed (ROCE) | 7.24 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.10 |
Taxes
Over the trailing twelve months, Hangzhou Biotest Biotech Co.,Ltd. has paid 19.20M in income taxes, reflecting an effective tax rate of 15.21.
| Income Tax | 19.20M |
| Effective Tax Rate | 15.21 |
Stock Price Statistics
Hangzhou Biotest Biotech Co.,Ltd.'s stock has gained approximately 6.19601% over the past 52 weeks. The 50-day moving average sits at 37.85, while the 200-day moving average is 38.88.
| Beta (5Y) | N/A |
| 52-Week Price Change | 6.19601% |
| 50-Day Moving Average | 37.85 |
| 200-Day Moving Average | 38.88 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Hangzhou Biotest Biotech Co.,Ltd. generated 495.53M in revenue and converted that into 109.74M in net income, yielding earnings per share of 0.74. EBITDA reached 96.53M, while operating income came in at 96.53M.
| Revenue | 495.53M |
| Gross Profit | 260.89M |
| Operating Income | 96.53M |
| Pretax Income | 126.28M |
| Net Income | 109.74M |
| EBITDA | 96.53M |
| EBIT | 96.53M |
| Earnings Per Share (EPS) | 0.74 |
Balance Sheet
Hangzhou Biotest Biotech Co.,Ltd. holds 1.55B in cash and equivalents against 228,795.08 in total debt, resulting in a net debt position of -1.55B. Total book value stands at 1.54B, with working capital of 1.60B providing operational flexibility.
| Cash & Cash Equivalents | 1.55B |
| Total Debt | 228,795.08 |
| Net Debt | -1.55B |
| Equity (Book Value) | 1.54B |
| Book Value Per Share | 10.61 |
| Working Capital | 1.60B |
Cash Flow
After subtracting -83.20M in capital expenditures, free cash flow totaled -83.20M - equivalent to -0.57 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -83.20M |
| Free Cash Flow | -83.20M |
| FCF Per Share | -0.57 |
Margins
Hangzhou Biotest Biotech Co.,Ltd. operates with a gross margin of 52.65, reflecting its pricing power and cost economics. The operating margin of 19.48 and net profit margin of 22.15 provide insight into operational efficiency.
| Gross Margin | 52.65 |
| Operating Margin | 19.48 |
| Pretax Margin | 25.48 |
| Profit Margin | 22.15 |
| EBITDA Margin | 19.48 |
Dividends & Yields
The company's payout ratio of 154.75 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 1.11 |
| Dividend Yield | N/A |
| Payout Ratio | 154.75 |
| Shareholder Yield | 1.81 |
| FCF Yield | 1.60 |
Scores
Hangzhou Biotest Biotech Co.,Ltd. posts an Altman Z-Score of 26.81, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 26.81 |